Filtered By:
Cancer: Chronic Lymphocytic Leukemia
This page shows you your search results in order of date.
Order by Relevance | Date
Total 43 results found since Jan 2013.
HIF activation enhances Fc γRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
CONCLUSION: Our findings provide a detailed molecular and cellular basis for hypoxia driven resistance to antitumor mAb immunotherapy, unveiling a hitherto unexplored aspect of the TME. These findings provide a mechanistic rationale for the modulation of FcγRIIb expression or its blockade as a promising strategy to enhance approved and novel mAb immunotherapies.PMID:35392965 | DOI:10.1186/s13046-022-02294-5
Source: Cell Research - April 8, 2022 Category: Cytology Authors: Khiyam Hussain Rena Liu Rosanna C G Smith Kri T J M üller Mohammadmersad Ghorbani Sofia Macari Kirstie L S Cleary Robert J Oldham Russell B Foxall Sonya James Steven G Booth Tom Murray Lekh N Dahal Chantal E Hargreaves Robert S Kemp Jemma Longley James D Source Type: research
Cancers, Vol. 14, Pages 531: CARD9 Forms an Alternative CBM Complex in Richter Syndrome
n Mellert
Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, mostly diffuse large B-cell lymphoma (DLBCL). Despite intensive therapy, patients with RS have an unfavorable clinical outcome. The detailed pathobiology of Richter transformation still needs to be elucidated. Here, we report high mRNA and protein levels of CARD9 in the RS cell line U-RT1. Co-immunoprecipitation revealed the assembly of a CBM complex using CARD9 instead of CARD11. CARD9 is known to be an activator of NF-кB signaling in myeloid cells. U-RT1 Western blot analys...
Source: Cancers - January 21, 2022 Category: Cancer & Oncology Authors: Julia Maier Andr é Lechel Ralf Marienfeld Thomas F. E. Barth Peter M öller Kevin Mellert Tags: Article Source Type: research
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
Oncotarget. 2021 Mar 2;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 2.ABSTRACTThe glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces GLI1 expression in GLI1-unmutated CLL cells is unknown. Because signal transducer and activator of transcription 3 (STAT3) is constitutively activated in CLL cells and sequence analysis detected putative STAT3-binding sites in the GLI1 gene promoter, we hypo...
Source: Oncotarget - March 22, 2021 Category: Cancer & Oncology Authors: Uri Rozovski David M Harris Ping Li Zhiming Liu Preetesh Jain Taghi Manshouri Ivo Veletic Alessandra Ferrajoli Prithviraj Bose Phillip Thompson Nitin Jain Srdan Verstovsek William Wierda Michael J Keating Zeev Estrov Source Type: research
SIRP α Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients
In this study we examine whether the SIRPα axis regulates ADP responses to the anti-CD20 antibody, obinutuzumab, by NLCs. Using siRNA depletion strategies we show that SIRPα is a suppressor of ADP responses. Moreover, we show that this innate immune checkpoint contributes to the resistance phenotype in NLCs derived from CLL patients. Finally, we show that SIRPα suppression is mediated via the phosphatase, Shp1, which in turn suppresses SYK-dependent activation of ADP. Thus, we identify a druggable pathway that could be exploited to enhance sensitivity to existing therapeutic antibodies used in CLL. This is the first stu...
Source: Frontiers in Immunology - January 21, 2021 Category: Allergy & Immunology Source Type: research
TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.
CONCLUSIONS: TOSO might be involved in the pathogenesis of CLL by interacting with SYK, enhancing the BCR signaling pathway, and inducing apoptosis resistance.
PMID: 32784334 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - August 9, 2020 Category: General Medicine Authors: Zhang YR, Yu Z, Xiong WJ, Liu XX, Liu HM, Cui R, Wang Q, Chen WM, Qiu LG, Yi SH Tags: Chin Med J (Engl) Source Type: research
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells
ConclusionsThe increase of eEF1A1 in dead vs surviving patients may confer to eEF1A1 the role of a prognostic marker for CLL and possibly of a therapeutic target, given its involvement in MEC-1 survival. Specific aptamer/siRNA released by optimized delivery systems may allow the development of novel therapeutic options.Graphical abstract
Source: International Journal of Pharmaceutics - December 18, 2019 Category: Drugs & Pharmacology Source Type: research
